Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles

Biomaterials ◽  
2011 ◽  
Vol 32 (22) ◽  
pp. 5148-5157 ◽  
Author(s):  
Ling Xiao ◽  
Xiaoqin Xiong ◽  
Xiaohui Sun ◽  
Yanhong Zhu ◽  
Hao Yang ◽  
...  
2011 ◽  
Vol 14 (1) ◽  
pp. 67 ◽  
Author(s):  
Moorthi Chidambaram ◽  
R. Manavalan ◽  
K. Kathiresan

Cancer is one of the major causes of death worldwide and chemotherapy is a major therapeutic approach for the treatment which may be used alone or combined with other forms of therapy. However, conventional chemotherapy suffers lack of aqueous solubility, lack of selectivity and multidrug resistance. Nanotherapeutics is rapidly progressing aimed to solve several limitations of conventional drug delivery systems. Nonspecific target of cancer chemotherapy leads to damage rapidly proliferating normal cells and can be significantly reduced through folate and transferrin mediated nanotherapeutics which are aimed to target cancerous cells. Multidrug resistance is challenge in cancer chemotherapy which can be significantly reversed by solid lipid nanoparticles, polymeric nanoparticles, mesoporous silica nanoparticles, nanoparticulated chemosensitizer, nanoparticluated poloxamer and magnetic nanoparticles. Hydrophobic nature of chemotherapeutics leads to poor aqueous solubility and low bioavailability which can be overcome by nanocrystals, albumin based nanoparticles, liposomal formulation, polymeric micelles, cyclodextrin and chitosan based nanoparticles. This review focuses the role of nanotherapeutics to overcome lack of selectivity, multidrug resistance and lack of aqueous solubility of conventional cancer chemotherapy.


1997 ◽  
Vol 7 (14) ◽  
pp. 1909-1914 ◽  
Author(s):  
Charles J. Stankovic ◽  
Narayanan Surendran ◽  
Elizabeth A. Lunney ◽  
Mark S. Plummer ◽  
Kimberly S. Para ◽  
...  
Keyword(s):  

2004 ◽  
Vol 238 (1) ◽  
pp. 267-272 ◽  
Author(s):  
Anne Olliver ◽  
Michel Vallé ◽  
Elisabeth Chaslus-Dancla ◽  
Axel Cloeckaert

2015 ◽  
Vol 2015 ◽  
pp. 1-13 ◽  
Author(s):  
Carolina Soekmadji ◽  
Colleen C. Nelson

Emerging evidence has shown that the extracellular vesicles (EVs) regulate various biological processes and can control cell proliferation and survival, as well as being involved in normal cell development and diseases such as cancers. In cancer treatment, development of acquired drug resistance phenotype is a serious issue. Recently it has been shown that the presence of multidrug resistance proteins such as Pgp-1 and enrichment of the lipid ceramide in EVs could have a role in mediating drug resistance. EVs could also mediate multidrug resistance through uptake of drugs in vesicles and thus limit the bioavailability of drugs to treat cancer cells. In this review, we discussed the emerging evidence of the role EVs play in mediating drug resistance in cancers and in particular the role of EVs mediating drug resistance in advanced prostate cancer. The role of EV-associated multidrug resistance proteins, miRNA, mRNA, and lipid as well as the potential interaction(s) among these factors was probed. Lastly, we provide an overview of the current available treatments for advanced prostate cancer, considering where EVs may mediate the development of resistance against these drugs.


Sign in / Sign up

Export Citation Format

Share Document